{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Greenwich LifeSciences, Inc."},"Symbol":{"label":"Symbol","value":"GLSI"},"Address":{"label":"Address","value":"3992 BLUEBONNET DRIVE,BUILDING 14, STAFFORD, Texas, 77477, United States"},"Phone":{"label":"Phone","value":"+1 832 819-3232"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Greenwich LifeSciences Inc is a biopharmaceutical company that is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in most breast cancers at low, intermediate, and high or overexpressor levels."},"CompanyUrl":{"label":"Company Url","value":"https://www.greenwichlifesciences.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"F. Joseph Daugherty","title":"Director & Chief Medical Officer"},{"name":"Jaye L. Thompson","title":"Vice President-Clinical & Regulatory Affairs"},{"name":"Snehal S. Patel","title":"Chief Executive & Financial Officer, Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}